Compositions and methods for treating skin conditions using light and glucosamine hydrochloride

Abstract

The present invention provides compositions, methods and kits for treating skin, which combine administration of glucosamine hydrochloride and red light having a peak wavelength of about 600 nm to about 750 nm, near infrared light having a peak wavelength of about 750 nm to about 1000 nm, or both.

Claims

1. A method of treating skin, comprising topically applying to skin in need of treatment for signs of skin aging a topical composition comprising up to about 2 weight percent of glucosamine hydrochloride, and exposing said skin to both red light having a peak wavelength of about 600 nm to about 750 nm and near infrared light having a peak wavelength of about 750 nm to about 1000 nm, using a light delivery device, wherein the intensity of the light is below about 20 mW/cm.sup.2.

2. The method of claim 1, wherein the signs of skin aging are fine lines and wrinkles.

3. The method of claim 1, wherein the topical composition has a pH of about 3.0 to about 5.5.

4. The method of claim 1 further comprising exposing said skin to ultrasonic energy.

5. The method of claim 4, wherein the light delivery device delivers light and ultrasonic energy.

6. A method of treating skin, comprising topically applying to skin in need of moisturization a topical composition comprising up to about 2 weight percent of glucosamine hydrochloride, and exposing said skin to both red light having peak wavelength of about 600 nm to about 750 nm and near infrared light having a peak wavelength of about 750 nm to about 1000 nm, using a light delivery device, wherein the intensity of the light is below about 20 mW/cm.sup.2.

7. The method of claim 6, wherein the signs of skin aging are fine lines and wrinkles.

8. The method of claim 6, wherein the topical composition has a pH of about 3.0 to about 5.5.

9. The method of claim 6 further comprising exposing said skin to ultrasonic energy.

10. The method of claim 9, wherein the light delivery device delivers light and ultrasonic energy.

Description

EXAMPLE 1

(1) The activities of the following test treatments for production of hyaluronic acid were compared using the in vitro method described above using an untreated sample as the control: a) a combination of 633 nm red and 830 nm IR light (0.3 J/cm.sup.2 each), b) a combination of 633 nm red and 830 nm IR light (3 J/cm.sup.2 each), c) 0.02% glucosamine HCl in cell media solution, d) 0.2% glucosamine HCl in cell media solution, e) simultaneous application of a combination of red and IR light (0.3 J/cm.sup.2 each) and 0.02% glucosamine HCl in cell media solution, and f) simultaneous application of a combination of red and IR light (3 J/cm.sup.2 each) and 0.2% glucosamine HCl in cell media solution.

(2) The results are shown in Table 1.

(3) TABLE-US-00001 TABLE 1 Change in HA Fold Change HA concentration versus treat- concentrations over Untreated ment with Treatment (ng/ml) (ng/ml) light alone Untreated 551 0 — Red + NIR light 1412 +861 — (0.3 J/cm.sup.2 each) Red + NIR light 1828 +1277 — (3 J/cm.sup.2 each) 0.02% Glucosamine HCl 543 −8 — 0.2% Glucosamine HCl 999 +448 — Red + NIR Light 2489 +1938 2.25 (0.3 J/cm.sup.2) + 0.02% Glucosamine HCl Red + NIR Light 4379 +3828 2.99 (3 J/cm.sup.2) + 0.02% Glucosamine HCl Red + NIR Light 2260 +1709 1.98 (0.3 J/cm.sup.2) + 0.2% Glucosamine HCl Red + NIR Light 3873 +3322 2.60 (3 J/cm.sup.2) + 0.2% Glucosamine HCl

(4) Treatments of a combination of red and near infrared light and glucosamine HCl synergistically increased the hyaluronic acid secretion in the human dermal fibroblasts over treatment with the light alone.

EXAMPLE 2

(5) Using the same test method as Example 1, the treatments shown in Table 2 were applied to human dermal fibroblasts. Glucosamine phosphate was used instead of glucosamine hydrochloride.

(6) No synergy was observed.

(7) TABLE-US-00002 TABLE 2 Change in HA Fold Change HA concentration versus treat- concentrations over Untreated ment with Treatment (ng/ml) (ng/ml) light alone Untreated 740 0 Red + NIR light 1572 832 (0.3 J/cm.sup.2 each) 0.02% Glucosamine 689 −51 phosphate Red + NIR Light 1037 297 0.36 (0.3 J/cm.sup.2each) + 0.02% Glucosamine Phosphate

EXAMPLE 3

(8) Using the same test method as Example 1, the treatments shown in Table 3 were applied to human dermal fibroblasts. N-acetyl glucosamine was used instead of glucosamine hydrochloride.

(9) No synergy was observed.

(10) TABLE-US-00003 TABLE 3 Change in HA Fold Change HA concentration versus treat- concentrations over Untreated ment with Treatment (ng/ml) (ng/ml) light alone Untreated 860 0 Red + NIR light 1784 924 (0.3 J/cm.sup.2 each) 0.02% N-acetyl 735 −125 Glucosamine Red + NIR Light 1878 1018 1.1 (0.3 J/cm.sup.2 each) + 0.02% N-acetyl Glucosamine

EXAMPLE 4

(11) Topical compositions comprising glucosamine hydrochloride were prepared using the ingredients shown in Table 4 at pH values ranging from 4 to 5.5 by adjusting the amount of sodium hydroxide. Those compositions having a pH above 5.5 were not physically stable when evaluated visually for appearance and color after 7 days at 60° C. or after 30 days at 50° C.

(12) TABLE-US-00004 TABLE 4 US INCI % wt Water 79.84 Sodium Bisulfite 0.1 Citric Acid 0.5 Sodium Citrate 0.13 Polyacrylate Crosspolymer-6 0.8 Chlorphenesin 0.2 Cetearyl Olivate; Sorbitan Olivate 0.5 Glycerin 8 Polyisobutene; Polysorbate 20; 1.5 Polyacrylate-13 Dimethicone; Dimethicone Crosspolymer 1 Dimethicone 2.88 Dimethicone; Dimethiconol 1.5 Ethylhexylglycerin; Phenoxyethanol 0.8 Glucosamine HCl 1 Sodium Hydroxide 0.25 Water 1 Total: 100

EXAMPLE 5

(13) Two topical compositions for use in the claimed invention were prepared using the ingredients shown in Tables 5 and 6. The topical composition of Table 5 contained 0.1% by weight sodium bisulfite. The topical composition of Table 6 did not contain sodium bisulfite.

(14) When tested for physical stability using the method described in Example 4, the composition of Table 5 showed improved color and appearance compared with the composition of Table 6.

(15) TABLE-US-00005 TABLE 5 US INCI % wt Water 79.97 Sodium Bisulfite 0.1 Citric Acid 0.5 Polyacrylate Crosspolymer-6 0.8 Chlorphenesin 0.2 Cetearyl Olivate; Sorbitan Olivate 0.5 Glycerin 8 Polyisobutene; Polysorbate 20; 1.5 Polyacrylate-13 Dimethicone; Dimethicone Crosspolymer 1 Dimethicone 2.88 Dimethicone; Dimethiconol 1.5 Ethylhexylglycerin; Phenoxyethanol 0.8 Glucosamine HCl 1 Sodium Hydroxide 0.25 Water 1 Total: 100

(16) TABLE-US-00006 TABLE 6 US INCI % wt Water 80.07 Citric Acid 0.5 Polyacrylate Crosspolymer-6 0.8 Chlorphenesin 0.2 Cetearyl Olivate; Sorbitan Olivate 0.5 Glycerin 8 Polyisobutene; Polysorbate 20; 1.5 Polyacrylate-13 Dimethicone; Dimethicone Crosspolymer 1 Dimethicone 2.88 Dimethicone; Dimethiconol 1.5 Ethylhexylglycerin; Phenoxyethanol 0.8 Glucosamine HCl 1 Sodium Hydroxide 0.25 Water 1 Total: 100

(17) The compositions of Table 7 were also prepared. Compositions A and B contained either BHT or Tocopheryl Acetate, known antioxidants, instead of sodium bisulfite (Composition C). However, neither Composition A nor Composition B showed improvement in physical stability versus Composition C when tested in the manner set forth in Example 4.

(18) TABLE-US-00007 TABLE 7 A B C US INCI % wt % wt % wt Water 80.62 80.69 80.64 Disodium EDTA 0.2 0.2 0.2 BHT 0.12 — — Tocopheryl Acetate — 0.05 — Sodium Bisulfite — — 0.1 Polyacrylate Crosspolymer-6 0.8 0.8 0.8 Chlorphenesin 0.2 0.2 0.2 Cetearyl Olivate; Sorbitan Olivate 0.5 0.5 0.5 Glycerin 8 8 8 Polyisobutene; Polysorbate 20; 1.5 1.5 1.5 Polyacrylate-13 Dimethicone; Dimethicone Crosspolymer 1 1 1 Dimethicone 3.5 3.5 3.5 Dimethicone; Dimethiconol 1.5 1.5 1.5 Ethylhexylglycerin; Phenoxyethanol 0.8 0.8 0.8 Glucosamine HCl 1 1 1 Sodium Hydroxide 0.13 0.13 0.13 Water 0.13 0.13 0.13 Total: 100 100 100